argenex SE (NASDAQ:ARGX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of argenex SE (NASDAQ:ARGX) have been given an average recommendation of “Moderate Buy” by the twenty-six research firms that are covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $982.3333.

ARGX has been the subject of a number of recent research reports. Wedbush boosted their price objective on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Stifel Nicolaus boosted their price target on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. HC Wainwright upped their price objective on argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Baird R W cut argenex from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 18th. Finally, Morgan Stanley lifted their target price on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th.

argenex Price Performance

NASDAQ:ARGX opened at $840.95 on Friday. argenex has a 1-year low of $510.05 and a 1-year high of $934.62. The company has a 50-day moving average of $872.49 and a 200 day moving average of $742.33. The firm has a market cap of $51.78 billion, a PE ratio of 36.11, a price-to-earnings-growth ratio of 0.87 and a beta of 0.38.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. Sell-side analysts anticipate that argenex will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

Several institutional investors and hedge funds have recently made changes to their positions in ARGX. Ameriflex Group Inc. purchased a new position in argenex during the third quarter valued at approximately $32,000. Sunbelt Securities Inc. acquired a new stake in shares of argenex in the third quarter valued at about $36,000. Bessemer Group Inc. grew its position in shares of argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after purchasing an additional 47 shares in the last quarter. Mather Group LLC. purchased a new position in shares of argenex during the 3rd quarter worth $50,000. Finally, Rossby Financial LCC boosted its holdings in argenex by 115.2% in the 3rd quarter. Rossby Financial LCC now owns 71 shares of the company’s stock valued at $54,000 after purchasing an additional 38 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.